scispace - formally typeset
C

C Carbonell-Abella

Researcher at Autonomous University of Barcelona

Publications -  13
Citations -  412

C Carbonell-Abella is an academic researcher from Autonomous University of Barcelona. The author has contributed to research in topics: Population & Hip fracture. The author has an hindex of 5, co-authored 12 publications receiving 323 citations. Previous affiliations of C Carbonell-Abella include Carlos III Health Institute & University of Barcelona.

Papers
More filters
Journal ArticleDOI

The association between fracture and obesity is site-dependent: a population-based study in postmenopausal women.

TL;DR: The association between obesity and fracture in postmenopausal women is site‐dependent, obesity being protective against hip and pelvis fractures but associated with an almost 30% increase in risk for proximal humerus fractures when compared with normal/underweight women.
Journal ArticleDOI

Association of Tramadol vs Codeine Prescription Dispensation With Mortality and Other Adverse Clinical Outcomes.

TL;DR: In this article, the authors compared the associations of tramadol compared with codeine, with mortality and other adverse clinical outcomes as used in outpatient settings, and found that tramadols were significantly associated with a higher risk of all-cause mortality, cardiovascular events, fractures, constipation, delirium, falls, opioid abuse/dependence, and sleep disorders within 1 year after the first dispensation.
Journal ArticleDOI

Excess of all-cause mortality after a fracture in type 2 diabetic patients: a population-based cohort study

TL;DR: In this paper, the authors reported an absolute and relative excess post-fracture mortality following a fracture in type 2 diabetes mellitus (T2DM) patients compared to non-diabetic patients.
Journal ArticleDOI

Early (1-year) Discontinuation of Different Anti-osteoporosis Medications Compared: A Population-Based Cohort Study

TL;DR: Monthly risedronate, weekly alendronsate, and daily teriparatide are the drugs with the best persistence, whilst daily oral drugs have 40–60 % higher first-year discontinuation rates compared toweekly alendronate.